Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Chlorine dioxide was discussed as a potential hair growth treatment, with a method involving spraying it on the scalp and covering it with a cap. Concerns were raised about its safety, comparing it to bleach.

Clascoterone is nearing regulatory submission as a potential new treatment for androgenetic alopecia, with positive Phase III results, while discussions continue about other treatments like PP405, minoxidil, and finasteride. Some users express excitement for clascoterone and Breezula, despite concerns about the effectiveness and practicality of topical treatments.

FLEAVA is accused of scamming customers by enrolling them in unwanted monthly subscriptions for Advanced Copper Peptide without consent. Many users struggled to get refunds and reported ongoing charges despite cancellation requests.

The conversation is about using Winlevi Clascoterone cream for hair loss. The user is considering adding it to their routine, which includes a topical hair growth serum, and is seeking feedback on its effectiveness.

RU58841 can be ordered as a powder and compounded at home, but it should be stored at room temperature to avoid crystallization. Pyraulatmide may follow a similar principle.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

A user asks about experiences with Minichek F 5% with Procapil, specifically its drying time. Responses discuss the effectiveness and drying time of the treatment.

Topical 1% cetirizine is more effective for hair growth than 10 mg oral cetirizine. It can be ordered online from specific hair loss companies.

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

Koshine KX-826 has different versions, and the green version uses a plant-based carrier that may be less irritating for those sensitive to propylene glycol. Users report irritation with some versions of KX-826.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

Clascoterone is considered overhyped and not as effective as finasteride or dutasteride, but it may be useful as a supportive treatment in combination with other therapies. Users express skepticism about its effectiveness compared to clinical trials, with some suggesting it could be beneficial for those who cannot tolerate other treatments.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

A user is making a 2-Deoxy-D-ribose solution and asks if it can be put into an oil instead of a gel, considering adding hydrocortisone and retinoic acid. They seek advice on the best carrier oil for hair growth.

The user started finasteride two weeks ago and has been using minoxidil for over a month, while also supplementing with Acetyl L-Carnitine. They are curious if others have experienced hair shedding or growth with Acetyl L-Carnitine, especially when used with finasteride and minoxidil.

The conversation discusses concerns about using cordyceps while on dutasteride due to potential DHT increase, with OP experiencing hair loss after using creatine. OP is advised to stop creatine and give dutasteride more time to evaluate its effectiveness.

Combining therapies like scyllo-inositol, alpha-ketoglutarate, and autophagy-inducing supplements may enhance hair growth and prevent hair loss. Reporting individual results can accelerate progress in hair loss treatments.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

Clascoterone phase 3 results show promising improvements in hair count, but concerns about high costs and lack of detailed data remain. Users compare it to existing treatments like Minoxidil and Finasteride, expressing skepticism about its accessibility and effectiveness.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.

Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.

The conversation discusses a topical finasteride therapy with hydrocortisone butyrate, estrone base, and breviline. A user suggests oral finasteride as a superior option.

A user discusses a hair loss treatment combining minoxidil and tretinoin, noting it may enhance absorption. Some users express interest and share positive experiences, while others question its effectiveness without medical evidence.

The conversation discusses using NAC (N-Acetyl Cysteine) alongside minoxidil and finasteride for hair loss, with some users noting potential hairline improvement and increased energy. The original poster reduced their finasteride dosage due to mental decline and anxiety, and while NAC's effects on hair are anecdotal, it is considered low-risk with other health benefits.

The conversation discusses hair loss treatments, specifically seeking a 15% glycyrrhizic acid formula without additional ingredients. It also mentions the potential opposite effects of glycyrrhizic acid on humans compared to rats.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

The user is using ketoconazole shampoo, organic vinegar, iced aloe vera gel, and sulfur soap to address hair loss, avoiding minoxidil and finasteride unless necessary. Some users see improvement, while others suggest adding finasteride for better results.

The conversation discusses creating a customized minoxidil formulation with tretinoin, azelaic acid, and caffeine, but there are concerns about foam stabilization due to acidity. The user seeks advice on the best formulation for effective results.

Azelaic acid is discussed for its anti-inflammatory and anti-fungal properties, which can improve scalp health and potentially boost hair growth. It is suggested for topical use, especially alongside minoxidil.